Barclays PLC Boosts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Barclays PLC raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 187.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 219,331 shares of the biotechnology company's stock after purchasing an additional 143,072 shares during the period. Barclays PLC owned 0.15% of Aurinia Pharmaceuticals worth $1,607,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC grew its position in Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock worth $93,000 after purchasing an additional 3,919 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Aurinia Pharmaceuticals by 10.0% during the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company's stock worth $301,000 after buying an additional 4,808 shares during the period. Handelsbanken Fonder AB grew its holdings in shares of Aurinia Pharmaceuticals by 13.2% during the third quarter. Handelsbanken Fonder AB now owns 60,700 shares of the biotechnology company's stock valued at $445,000 after buying an additional 7,100 shares during the last quarter. PFG Investments LLC increased its position in shares of Aurinia Pharmaceuticals by 37.9% in the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company's stock valued at $164,000 after acquiring an additional 7,900 shares during the period. Finally, CWM LLC raised its stake in Aurinia Pharmaceuticals by 247.7% in the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company's stock worth $84,000 after acquiring an additional 8,180 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on AUPH. StockNews.com upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $10.00.

Insider Activity at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now directly owns 13,356 shares of the company's stock, valued at $112,591.08. This represents a 25.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is owned by company insiders.

Aurinia Pharmaceuticals Stock Performance

AUPH traded down $0.27 during midday trading on Friday, hitting $8.07. 2,415,022 shares of the company were exchanged, compared to its average volume of 1,667,224. The company's 50 day simple moving average is $8.74 and its 200 day simple moving average is $7.24. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -53.80 and a beta of 1.24. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.